Research
Hormonal
Exaggerated secretion of GLP-1 following RYGB and sleeve gastrectomy is causally responsible for improved postprandial beta-cell function and glucose tolerance, as demonstrated by the reversal of these benefits when GLP-1 receptors are blocked.
Surgery triggers a natural surge in GLP-1, a hormone that boosts insulin and improves blood sugar control. This hormonal boost is so effective that blocking it reverses the surgery's benefits, confirming GLP-1's central role in diabetes remission.
StrongSupportsVERY_HIGH confidence
blockade of the GLP-1 receptor in RYGB and sleeve gastrectomy patients consistently results in diminished postprandial insulin secretion as well as impairments in glucose tolerance, and can correct postprandial hypoglycaemia, confirming the causative role of exaggerated GLP-1 secretion in improved beta-cell function
Why this rating
Based on multiple human studies using specific GLP-1 receptor antagonists (Exendin 9-39) to demonstrate causality.
Source
Updates in weight loss surgery and gastrointestinal peptides
Maria S. Svane et al. · Current Opinion in Endocrinology Diabetes and Obesity · 2015
DOI 10.1097/med.0000000000000131
narrative_reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy improve glucose metabolism and induce weight loss primarily through accelerated nutrient transit to the distal small intestine, which triggers exaggerated secretion of L-cell hormones (GLP-1, PYY) that enhance insulin secretion and suppress appetite.Good
- The early improvement in hepatic insulin sensitivity after RYGB is primarily driven by postoperative caloric restriction and reduced liver fat, rather than surgery-specific anatomical effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →